OCGN Ocugen Inc
Price (delayed)
$0.7027
Market cap
$204.71M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.18
Enterprise value
$172.49M
Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. Its breakthrough modifier
Highlights
The EPS has grown by 49% year-on-year
OCGN's quick ratio has surged by 178% since the previous quarter but it is down by 49% year-on-year
The equity has soared by 140% QoQ but it fell by 30% YoY
The debt has grown by 4.8% YoY
Key stats
What are the main financial stats of OCGN
Market
Valuations
Earnings
Shares outstanding
291.32M
Market cap
$204.71M
Enterprise value
$172.49M
Price to earnings (P/E)
N/A
Price to book (P/B)
4.98
Price to sales (P/S)
20.96
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
18.49
Revenue
$9.33M
Gross profit
$9.33M
Operating income
-$49.54M
Net income
-$49.67M
EBIT
-$49.67M
EBITDA
-$47.35M
Free cash flow
-$49.17M
Per share
Balance sheet
Liquidity
EPS
-$0.18
EPS diluted
-$0.18
Free cash flow per share
-$0.18
Book value per share
$0.14
Revenue per share
$0.03
TBVPS
$0.22
Total assets
$61.94M
Total liabilities
$21.31M
Debt
$6.78M
Equity
$40.63M
Working capital
$24.91M
Debt to equity
0.17
Current ratio
2.58
Quick ratio
2.47
Net debt/EBITDA
0.68
Margins
Efficiency
Dividend
EBITDA margin
-507.6%
Gross margin
100%
Net margin
-532.5%
Operating margin
-531.1%
Return on assets
-81.7%
Return on equity
-139.2%
Return on invested capital
-339.4%
Return on capital employed
-107.6%
Return on sales
-532.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
OCGN stock price
How has the Ocugen stock price performed over time
Intraday
6.47%
1 week
-3.04%
1 month
-6.47%
1 year
15.2%
YTD
-12.71%
QTD
-12.71%
Financial performance
How have Ocugen's revenue and profit performed over time
Revenue
$9.33M
Gross profit
$9.33M
Operating income
-$49.54M
Net income
-$49.67M
Gross margin
100%
Net margin
-532.5%
The company's operating margin has surged by 54% YoY but it fell by 30% QoQ
The net margin has soared by 52% YoY but it has contracted by 31% from the previous quarter
The operating income rose by 40% year-on-year
The net income rose by 38% YoY but it fell by 2.6% QoQ
Growth
What is Ocugen's growth rate over time
Valuation
What is Ocugen stock price valuation
P/E
N/A
P/B
4.98
P/S
20.96
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
18.49
The EPS has grown by 49% year-on-year
The equity has soared by 140% QoQ but it fell by 30% YoY
The price to book (P/B) is 61% less than the last 4 quarters average of 12.0 and 43% less than the 5-year quarterly average of 8.2
The price to sales (P/S) is 37% less than the last 4 quarters average of 31.0
OCGN's revenue is up by 31% YoY but it is down by 22% from the previous quarter
Efficiency
How efficient is Ocugen business performance
The return on sales has surged by 52% year-on-year but it has declined by 31% since the previous quarter
The ROIC has grown by 41% YoY but it has contracted by 7% from the previous quarter
OCGN's ROE is down by 22% year-on-year and by 17% since the previous quarter
The return on assets has declined by 9% since the previous quarter but it has grown by 5% year-on-year
Dividends
What is OCGN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for OCGN.
Financial health
How did Ocugen financials performed over time
OCGN's total assets is 191% greater than its total liabilities
OCGN's quick ratio has surged by 178% since the previous quarter but it is down by 49% year-on-year
The current ratio has surged by 148% since the previous quarter but it has declined by 49% year-on-year
The debt is 83% less than the equity
The equity has soared by 140% QoQ but it fell by 30% YoY
The debt to equity has dropped by 59% since the previous quarter but it has surged by 55% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.